Ulcerative ColitisPhase 2AegeanNCT07513181
Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
A Phase 2 study testing ATH-063 in people with Ulcerative Colitis and Inflammatory Bowel Diseases, run by Athos Therapeutics Inc at 4 sites in United States.
Trial summary
The primary objective of this trial is to evaluate the clinical efficacy of ATH-063 in participants with biologic/advanced therapy relapsed/refractory moderately to severely active UC. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Ulcerative Colitis, Inflammatory Bowel Diseases, Autoimmune Diseases
- What is being tested?
- ATH-063
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 120 participants
- Where
- 4 sitesUnited States
- Study dates
- 30 Apr 2026to 14 Dec 2028
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Able to understand and willing to provide informed consent and able to comply with the trial procedures and restrictions.
- Male or female (assigned at birth, inclusive of all gender identities) participants 18 to 75 years of age, inclusive, at the time of informed consent.
- Male or female participants must be postmenopausal/surgically sterile, sexually abstinent, or using 2 forms of protocol-specified contraception, including 1 physical barrier method (condom or diaphragm) plus 1 highly effective method (ie, hormonal contraception., intrauterine device, intrauterine hormone-releasing system, bilateral occlusion, vasectomy, or complete sexual abstinence). Women of childbearing potential (WOCBP) must also be nonpregnant and not breastfeeding.
- Has a diagnosis of UC confirmed by endoscopic and histologic evidence at least 4 months before screening. If confirmation is not available in source documentation, the screening endoscopy and histology reports for this trial may serve as evidence.
- Has moderately to severely active UC, defined as a UCDSS of 5 to 9, with an EMA subscore of 2 to 3 (obtained during the central review of the screening video endoscopy).
- Has active UC that extends >15 cm beyond the anal verge, as identified at the screening colonoscopy.
Show all 18Show fewer
- Has documentation of moderately to severely active UC that is refractory (inadequate response - signs and symptoms of persistently active disease despite induction treatment at the approved induction dosing indicated in the product label; or loss of response - recurrence of signs and symptoms of active disease during maintenance dosing following prior clinical benefit [discontinuation despite clinical benefit does not qualify as having failed biologic therapy]) to 1 to 2 prior approved biologic/advanced UC therapies (ie, biologic therapies, such as antitumor necrosis factor [TNF], anti-integrin, and anti-interleukin [IL]-12/23 therapies; or advanced therapies, such as sphingosine 1-phosphate [S1P] receptor modulators and Janus kinase [JAK] inhibitors [eg, tofacitinib]; one of which must have been an anti-TNF therapy; the other, if applicable, may have had the same or a different mechanism of action) when given at doses approved for the treatment of UC.
- Has documentation of an inadequate response, loss of response, or intolerance to conventional standard-of-care therapy with corticosteroids (ie, prednisone and budesonide), 5-ASAs (ie, mesalamine, sulfasalazine), or other immunomodulators (ie, thiopurines, methotrexate, cyclosporine, and tacrolimus).
- Any prior therapy, including any investigational drug, not permitted as concomitant standard-of-care therapy must have been discontinued for at least 4 weeks or 5 half-lives prior to screening, whichever is longer, or the participant must have no active drug detected at the start of screening, as determined by therapeutic drug monitoring.
- Has screening laboratory test results within the following parameters:
- Hemoglobin ≥8 g/dL
- White blood cell (WBC) ≥3×103/μL
- Neutrophil count ≥1.5×103/μL
- Platelet count ≥100,000/μL
- Serum creatinine ≤1.5 mg/dL and/or creatinine clearance >80 mL/min
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values must be within 2× the upper limit of normal (ULN) for the laboratory conducting the test
- Total bilirubin ≤1.5×ULN at screening in participants who do not have Gilbert's syndrome
- Total bilirubin ≤2×ULN at screening in participants with Gilbert's syndrome
Who cannot join
- Clinically significant abnormal medical history, or abnormal findings on physical examination, vital signs, ECG, or laboratory tests at screening, that the investigator judges as likely to interfere with the objectives of the trial or the safety of the participant.
- Surgery (eg, stomach bypass) or medical condition that might significantly affect absorption of oral medicines (as judged by the investigator).
- Hospitalization for exacerbation of UC requiring intravenous (IV) corticosteroids (ie, UC flare) within 12 weeks prior to screening.
- Current evidence of fulminant colitis, toxic megacolon, or recent history (within 6 months prior to screening) of toxic megacolon, or bowel perforation.
- Investigator judgment that the participant is likely to require a colectomy within 12 weeks of the start of trial medication administration.
- Has UC that is limited to the rectum or right colon.
Show all 27Show fewer
- Presence or history of an enteric fistula consistent with Crohn's disease (CD).
- History of ischemic colitis.
- History of indeterminate colitis or microscopic colitis.
- History of radiation colitis.
- History of CD.
- History of colonic stricture.
- Positive stool test result for Clostridioides difficile (C. difficile), bacterial infection, or ova and parasites at screening (for bacterial infections, only exclusionary if the active infection requires antibiotic treatment).
- History or evidence of any extensive colonic resection or subtotal or total colectomy (with or without presence of a stoma or ileoanal pouch) that would prevent adequate evaluation of trial intervention on clinical disease activity, as per the investigator's judgment.
- Current colonic adenomas, dysplasia, or past confirmed colonic dysplasia that has not been eradicated (participants who have had UC >8 years should have had a colonoscopy to screen for dysplasia within 1 year prior to the screening visit, or this can be performed as part of the screening colonoscopy). A participant with prior history of adenomatous polyps will be eligible if the polyps have been completely removed (documented), and the participant is free of polyps and does not have evidence of dysplasia on histologic evaluation at screening.
- Any current malignancy judged by the investigator not to be in full remission (except for basal cell and in situ squamous cell carcinomas of the skin that have been fully excised and resolved). Prior malignancy must have been in remission for >2 years prior to screening.
- Exposure to >2 prior approved biologic/advanced UC therapies (as defined in Inclusion Criterion) when given at doses approved for the treatment of UC.
- Use of agents that deplete B or T cells (eg, rituximab) within 12 months of first trial medication administration.
- Participants with potentially active hepatitis B virus (HBV) infection or at risk of reactivation of HBV infection; hepatitis C virus (HCV) antibody (anti-HCV) or HCV RNA (unless history of HCV that has been cleared and documented with sustained virologic response for >2 years); or human immunodeficiency virus antibodies (anti-HIV)1/2 at screening.
- Has severe, progressive, or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurologic, psychiatric, or cerebral disease; or signs or symptoms thereof.
- History of, or concurrent, unstable ischemic heart disease or severe congestive heart failure (New York Heart Association Class III or IV).
- History of alcohol or drug abuse or dependence within 1 year before screening that, in the opinion of the investigator, would impair the ability of the participant to comply with trial protocol requirements.
- Female participants who are pregnant, breastfeeding, or planning to become pregnant during the trial.
- Receiving tube feeding, defined formula diets, or total parenteral alimentation.
- History of bleeding disorders or recent use of antiplatelet or antithrombotic agents that in the investigator's judgment preclude safely performing endoscopic procedures and biopsy within the timeframe outlined in the trial protocol.
- Use of drugs that are inhibitors of P-glycoprotein (P-gp; eg, amiodarone, clarithromycin, cyclosporine, ketoconazole, ritonavir, verapamil) or breast cancer resistance protein (BCRP; eg, Cyclosporin A, tacrolimus, gefitinib).
- Any other condition that precludes adequate understanding, cooperation, and compliance with trial procedures or any condition that could pose a risk to the participant's safety (including any known hypersensitivity to the trial medication products), as per the investigator's judgment.
Trial locations and contacts
4 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States4 sites, 4 recruiting
- Recruiting
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
Dr. Benjamin Cohen
- Recruiting
Miami Clinical Research
Miami, Florida, 33155
Dr. Keila Hoover
- Recruiting
Gastroenterology Consultants, P.C.
Roswell, Georgia, 30076
Dr. Melvin Bullock
- Recruiting
GCP Clinical Research
Tampa, Florida, 33609
Dr. Alan Weintraub
About this study
Official title: A Phase 2b, Double-Blind, Placebo-Controlled, Multicenter Proof of Concept Clinical Study to Evaluate the Efficacy and Safety of ATH-063 Induction Therapy in Patients With Biologic Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
The primary objective of this trial is to evaluate the clinical efficacy of ATH-063 in participants with biologic/advanced therapy relapsed/refractory moderately to severely active UC.
Read the detailed description
The trial will consist of a 4-week screening period, a 12-week double-blind treatment period, and an open-label extension. Following completion of the 12-week double-blind period, participants who wish to continue into the open-label extension will be unblinded.
Participants who do not wish to continue into the extension will remain blinded and proceed to posttreatment follow-up at Weeks 16 and 24 (via telephone calls). Unblinded participants who are revealed to have been randomized to receive ATH-063 will also proceed to posttreatment follow-up at Weeks 16 and 24 (via telephone calls). Unblinded participants revealed to have been randomized to receive placebo will receive open-label ATH-063 150 mg as three 50 mg capsules once daily (QD) from Week 12 to Week 24 with visits at Weeks 16, 20, and 24. At the end of the open-label treatment, these participants will proceed to posttreatment follow-up at Weeks 28 and 36.
- Being tested
- ATH-063, Placebo
- Keywords
- Colitis, Ulcerative, IBD, Biologic refractory
- Medical subject headings
- Colitis, Ulcerative, Inflammatory Bowel Diseases, Autoimmune Diseases, Colitis, Ulcer
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ATH-063Drug
Three 50 mg capsules, total dose 150 mg.
PlaceboOther
Identical capsule to the drug without the active ingredient.
| Study group | Role | What they receive |
|---|---|---|
| ATH-063 150 mg | Experimental | Participants will be randomized to receive ATH-063 150 mg orally QD for 12 weeks, with posttreatment follow-up at Weeks 16 and 24. Receives: Drug: ATH-063 |
| Placebo | Placebo comparator | Participants will be randomized to receive matching placebo orally QD for 12 weeks, with posttreatment follow-up at Weeks 16 and 24. Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical Remission at Week 12
Clinical remission is defined as a ulcerative colitis disease severity score (UCDSS) of 0 to 2, including the following components: a stool frequency subscore (SFS) of 0 (on a scale from 0 to 3, with higher scores indicating higher frequency) or an SFS of 1 with a decrease of at least 1 point from baseline; a rectal bleeding subscore (RBS) of 0; and a centrally read endoscopic mucosal appearance (EMA) subscore of 0 or 1. The UCDSS (0 to 9 points) is the sum of the following 3 components: RBS (0 to 3), SFS (0 to 3), and EMA subscore (0 to 3), with higher scores indicating more severe disease.
Measured: At Week 12
Secondary outcomes (5)
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Trial Discontinuation
Clinically significant changes in vital signs, electrocardiograms (ECGs), and safety laboratory analytes will be included as TEAEs.
Measured: Up to Week 36
Clinical Response at Week 12
Clinical response is defined as a decrease from baseline of ≥2 points and ≥30% in the UCDSS, plus either a decrease from baseline of ≥1 point in RBS (range 0 to 3, with higher scores denoting greater severity) or an absolute RBS of 0 or 1.
Measured: At Week 12
Change From Baseline in UCDSS at Week 12
The UCDSS (0 to 9 points) is the sum of the following 3 components: RBS (0 to 3), SFS (0 to 3), and EMA subscore (0 to 3), with higher scores indicating more severe disease.
Measured: At Week 12
Proportion of Participants Who Achieve FDA-defined Clinical remission at Week 12
Food and Drug Administration (FDA)-defined clinical remission is defined for purposes of this trial as a UCDSS of 0 to 2, including the following: an SFS of 0 or 1, an RBS of 0, and an EMA subscore of 0 or 1.
Measured: At Week 12
Clinical Response at Week 24 Among Participants Who Received Placebo During the First 12 Weeks and ATH-063 in a 12-week Follow-up
Clinical response is defined as a decrease from baseline of ≥2 points and ≥30% in the UCDSS, plus either a decrease from baseline of ≥1 point in RBS (range 0 to 3, with higher scores denoting greater severity) or an absolute RBS of 0 or 1.
Measured: From Week 12 to Week 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Apr 2026
- Study start30 Apr 2026
- Primary completion14 Dec 2028 (estimated)
- Study completion14 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ulcerative ColitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Athos Therapeutics Inc
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- David T. Rubin, MD, Study director, University of Chicago Biological Sciences Division
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07513181
- Sponsor's protocol ID
- ATH-002-000
- Other IDs
- 2024-520183-33-00
- Acronym
- Aegean
- Status last verified
- Sep 2026
- First submitted
- 1 Apr 2026
- Last updated
- 21 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No